A practical reference on phase 2 trial: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-12-22. Anything still debated is marked as such rather than presented as settled.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Contains non-natural residues |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist profile |
| Route of administration | Subcutaneous injection | In clinical trial settings |
| Development status | Investigational | Not approved in major markets |
| Approximate molecular mass | About 4.7 kDa | Peptide-scale molecule |
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
=== Imaging === The role of MRI or ultrasound imaging in the diagnosis of CTS is unclear. Their routine use is not recommended. Morphological MRI has high sensitivity but low specificity for CTS. High signal intensity may suggest accumulation of axonal transport, myelin sheath degeneration, or edema. However, more recent quantitative MRI techniques, which derive repeatable, reliable, and objective biomarkers from nerves and skeletal muscle, may have utility, including diffusion-weighted (typically diffusion tensor) MRI, which has demonstrable normal values and aberrations in carpal tunnel syndrome.
== Gas source mass spectrometry == Measurement of natural variations in the abundances of stable isotopes of the same element is normally referred to as stable isotope analysis. This field is of interest because the differences in mass between different isotopes leads to isotope fractionation, causing measurable effects on the isotopic composition of samples, characteristic of their biological or physical history. As a specific example, the hydrogen isotope deuterium (heavy hydrogen) is almost double the mass of the common hydrogen isotope. Water molecules containing the common hydrogen isotope (and the common oxygen isotope, mass 16) have a mass of 18. Water incorporating a deuterium atom has a mass of 19, over 5% heavier. The energy to vaporise the heavy water molecule is higher than that to vaporize the normal water so isotope fractionation occurs during the process of evaporation. Thus a sample of sea water will exhibit a quite detectable isotopic-ratio difference when compared to Antarctic snowfall. Samples must be introduced to the mass spectrometer as pure gases, achieved through combustion, gas chromatographic feeds, or chemical trapping. By comparing the detected isotopic ratios to a measured standard, an accurate determination of the isotopic make up of the sample is obtained. For example, carbon isotope ratios are measured relative to the international standard for C. The C standard is produced from a fossil belemnite found in the Peedee Formation, which is a limestone formed in the Cretaceous period in South Carolina, U.S.A.
Magnetic refrigeration, or adiabatic demagnetization, is a cooling technology based on the magnetocaloric effect, an intrinsic property of magnetic solids. The refrigerant is often a paramagnetic salt, such as cerium magnesium nitrate. The active magnetic dipoles in this case are those of the electron shells of the paramagnetic atoms. A strong magnetic field is applied to the refrigerant, forcing its various magnetic dipoles to align and putting these degrees of freedom of the refrigerant into a state of lowered entropy. A heat sink then absorbs the heat released by the refrigerant due to its loss of entropy. Thermal contact with the heat sink is then broken so that the system is insulated, and the magnetic field is switched off. This increases the heat capacity of the refrigerant, thus decreasing its temperature below the temperature of the heat sink. Because few materials exhibit the needed properties at room temperature, applications have so far been limited to cryogenics and research.
== Overview == The Japan Furikake Association defines furikake as "seasoned and dried one or more kinds of marine products, agricultural products, livestock products, etc., and mixed with seaweed, sesame seeds, seasonings, and others. Its main use is to be sprinkled (in Japanese: furikake) on rice and other foods." According to this definition, gomashio (sesame salt), which is traditionally sprinkled on red bean rice, and shiso, after being used to season umeboshi (pickled plums) and dried and powdered, are also furikake. Chazuke-no-moto, a mixture that becomes chazuke when hot green tea is poured on it after sprinkling on rice, is also similar to furikake.
Sources: en.wikipedia.org
Forensic analysis at the Hospital das Clínicas in São Paulo identified an incision in the jugular vein used to inject a solution of aromatic substances, such as camphor and myrrh, during the 19th century embalming. The preservation was attributed to this chemical process combined with the hermetic seal of her lead-lined casket, which prevented the growth of microorganisms. Before reinterment, researchers re-embalmed the remains using techniques analogous to the original vascular method.
==== Byzantine writers ==== Physician Oribasius (c. 320–403), personal physician of the emperor and philosopher Julian, compiled all known ancient medical texts of his time by theme into medical encyclopedia. He quotes Galen and Rufus on diabetes, considering it to be a polyuric disease of the kidneys. Various descriptive names are given for the condition, including: chamber-pot dropsy, diarrhea of the urine (diarrhea urinosa), and the thirsty disease. These descriptions, along with a number of other names for the condition ("liuria", "extreme thirst or dipsacus"), were echoed by later Byzantine writers in key encyclopedic texts.
Despite being lipophilic, T3 and T4 cross the cell membrane via carrier-mediated transport, which is ATP-dependent. T1a and T0a are positively charged and do not cross the membrane; they are believed to function via the trace amine-associated receptor TAAR1 (TAR1, TA1), a G-protein-coupled receptor located in the cytoplasm. Another critical diagnostic tool is measurement of the amount of thyroid-stimulating hormone (TSH) that is present.
=== Names === Lidocaine is the International Nonproprietary Name (INN), British Approved Name (BAN), and Australian Approved Name (AAN), while lignocaine is the former BAN and AAN. Both the old and new names will be displayed on the product label in Australia until at least 2023. Xylocaine is a brand name, referring to the major synthetic building block 2,6-xylidine. The "ligno" prefix is chosen because "xylo" means wood in Greek while "ligno" means the same in Latin. The "lido" prefix instead refers to the fact that the drug is chemically related to acetanilide.
The enzyme is a cytochrome P450 protein containing heme, isolated from maize and other grasses. It requires a partner cytochrome P450 reductase for functional expression. This uses nicotinamide adenine dinucleotide phosphate. It is involved in the biosynthesis of protective and allelopathic compounds such as DIMBOA in some plants.
Sources: en.wikipedia.org
Vaccine production and storage has great potential in transgenic plants. Vaccines are expensive to produce, transport, and administer, so having a system that could produce them locally would allow greater access to poorer and developing areas. As well as purifying vaccines expressed in plants it is also possible to produce edible vaccines in plants. Edible vaccines stimulate the immune system when ingested to protect against certain diseases. Being stored in plants reduces the long-term cost as they can be disseminated without the need for cold storage, don't need to be purified, and have long term stability. Also being housed within plant cells provides some protection from the gut acids upon digestion. However the cost of developing, regulating, and containing transgenic plants is high, leading to most current plant-based vaccine development being applied to veterinary medicine, where the controls are not as strict. Genetically modified crops have been proposed as one of the ways to reduce farming-related CO2 emissions due to higher yield, reduced use of pesticides, reduced use of tractor fuel and no tillage. According to a 2021 study, in EU alone widespread adoption of GE crops would reduce greenhouse gas emissions by 33 million tons of CO2 equivalent or 7.5% of total farming-related emissions.
Colloidal gold and various derivatives have long been among the most widely used labels for antigens in biological electron microscopy. Colloidal gold particles can be attached to many traditional biological probes such as antibodies, lectins, superantigens, glycans, nucleic acids, and receptors. Particles of different sizes are easily distinguishable in electron micrographs, allowing simultaneous multiple-labelling experiments. In addition to biological probes, gold nanoparticles can be transferred to various mineral substrates, such as mica, single crystal silicon, and atomically flat gold(III), to be observed under atomic force microscopy (AFM).
=== Spinal and biologics === Spinal and biologics is Medtronic's second-largest business. Medtronic is the world leader in spinal and musculoskeletal therapies. In 2007, Medtronic purchased Kyphon, a manufacturer and seller of spinal implants that are necessary for procedures like kyphoplasty. In May 2008, Medtronic Spine agreed to pay the US government $75 million to settle a qui tam lawsuit after a whistleblower alleged that Medtronic committed Medicare fraud. The company was charged with illegally convincing healthcare providers to offer kyphoplasty, a spinal fracture repair surgery, as an inpatient, not an outpatient, procedure to make thousands of dollars more in profits per surgery. A "special report" by writer Steven Brill in Time showed that according to Medtronic's quarterly SEC filing of October 2012, the company had, on average, a 75.1% profit margin on its spine products and therapies.
== Diagnosis == Joint hypermobility syndrome shares symptoms with other conditions such as Marfan syndrome and Ehlers-Danlos Syndrome. Hypermobility syndrome and Hypermobile Ehlers-Danlos syndrome are difficult to diffentiate, and the boundaries between them may be arbitrary. Hypermobility syndrome and hypermobile Ehlers-Danlos syndrome are both likely to have a variety of genetic causes. Generalized hypermobility is a common feature in hereditary connective tissue disorders and many features overlap, but often features are present that enable differentiating these disorders. Ehlers-Danlos Syndrome was defined based on its observable symptoms in the skin and joints. The inheritance pattern of Ehlers-Danlos syndrome varies by type. The arthrochalasia, classic, hypermobility and vascular forms usually have an autosomal dominant pattern of inheritance. Autosomal dominant inheritance occurs when one copy of a gene in each cell is sufficient to cause a disorder. In some cases, an affected person inherits the mutation from one affected parent. Other cases result from new (sporadic) gene mutations. Such cases can occur in people with no history of the disorder in their family. It is impossible to tell whether a person has EDS symptoms due to an inherited EDS gene, a spontaneous mutation that causes identical symptoms, or a problem in fetal development causes identical symptoms, without both knowing the genetic family history and performing a specialized genetic test. The results do not matter to clinical treatment of the symptoms.
Journal of Clinical Investigation (Papers Presented / Proceedings of the Fifty-Fourth Annual Meeting of the American Society for Clinical Investigation, April 30, 1962. 41 (6): 1340. Daly, M.M.; Deming, Q.B.; Raeff, V.M.; Brun, L.M. (October 1963). "Cholesterol Concentration and Cholesterol Synthesis in Aortas of Rats With Renal Hypertension" (PDF). Journal of Clinical Investigation. 42 (10): 1606–1612. doi:10.1172/JCI104845. PMC 289439. PMID 14074354. Adel, H.N.; Deming, Q.B.; Daly, M.M.; Raeff, V.M.; Brun, L.M. (October 1965). "The Effect of Experimental Hypertension on Cholesterol Synthesis in the Rat". Journal of Clinical and Laboratory Medicine. 66 (4): 571–581. PMID 5843085. Wolinsky, Harvey; Daly, Marie M. (November 1970). "A Method for the Isolation of Intima-Media Samples from Arteries". Proceedings of the Society for Experimental Biology and Medicine. 135 (2): 364–368. doi:10.3181/00379727-135-35052. PMID 4921030. S2CID 46610507. Daly, M.M. (May 1971). "Biosynthesis of squalene and sterols by rat aorta". Journal of Lipid Research. 12 (3): 367–375. doi:10.1016/S0022-2275(20)39518-3. PMID 5579265. Daly, Marie M. (September 1972). "Effects of Hypertension on the Lipid Composition of Rat Aortic Intima-Media". Circulation Research. 31 (3): 410–416. doi:10.1161/01.res.31.3.410. PMID 5057020. S2CID 12008214. Wolinsky, Harvey; Goldfischer, Sidney; Daly, Marie M.; Kasak, Lisa E.; Coltoff-Schiller, Bernice (April 1975). "Arterial Lysosomes and Connective Tissue in Primate Atherosclerosis and Hypertension". Circulation Research. 36 (4): 553–561. doi:10.1161/01.res.36.4.553.
Sources: en.wikipedia.org
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.
No. It remains investigational, and phase 3 results have not been fully published or reviewed by regulators. Official approval status should be confirmed through regulatory agencies rather than secondary sources.
The added glucagon receptor activity is the main difference in its mechanism. Whether that addition produces meaningful benefits in clinical outcomes is still being studied. Comparisons between compounds rest largely on indirect rather than head-to-head trial data.
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.